When was MEDiC founded?

MEDiC was founded in 2019 and raised its 1st funding round 4 years after it was founded.

Where is MEDiC located?

MEDiC is headquartered in San Carlos, United States.

Who is the current CEO of MEDiC?

Kyuho Han of MEDiC. They have also founded 1 company.

How many employees does MEDiC have?

As of May 31, 2026, the latest employee count at MEDiC is 17.

Is MEDiC a funded company?

MEDiC is a funded company, having raised a total of $13M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2023.

When was the latest funding round of MEDiC?

MEDiC's latest funding was a $***** Seed round on Oct 14, 2024, with participation from 2 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $535M in funding in 2026 to date.

Where does MEDiC rank among its competitors?

MEDiC ranks 15th amongst 65 active competitors, of which 20 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of MEDiC?

MEDiC's top competitors include Senti Bio, CRISPR Therapeutics and 64x Bio. Among them, Senti Bio secured the most recent funding round in May, 2026.

MEDiC - 2026 Company Profile, Team, Funding & Competitors

Company Details

MEDIC life sciences has developed CRISPR based cancer organoids for clinical trial research. The genome-scale CRISPR/Cas9 functional genomics tool has been incorporated into 3D cancer organoids based on the required cancer type to recapitulate genetic mutations in the tumors.

Website: www.medic-life-sciences.com/
Email ID: *****@medic-life-sciences.com

Key Metrics

Founded Year

2019

Location

San Carlos, United States

Stage

Seed

Total Funding

$13M in 2 rounds

Latest Funding Round

Seed, Oct 14, 2024, $*****

Investors

Illumina & 7 more

Ranked

15^th among 65 active competitors

Employee Count

17 as on May 31, 2026

Similar Companies

Senti Bio & 80 more

View MEDiC's full profile

MEDiC is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MEDIC Life Sciences CIN: 84-4826900 , United States, Active	Dec 31, 2018	-	-	-

MEDiC has raised a total funding of $13M over 2 rounds. Its first funding round was on 2023. Its latest funding round was a Seed round on Oct 14, 2024 for $*****. 2 investors participated in its latest round. MEDiC has 8 institutional investors.

Here is the list of recent funding rounds of MEDiC:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 14, 2024	3313452	Seed	2225998	1704298	1104268	6163840
2023	6709	Seed	5293	2447	Illumina & 5 more	4684

Access funding benchmarks and valuations. Sign up today!

View details of MEDiC's funding rounds and investors

The founders of MEDiC are Kyuho Han, Hong-pyo Lee and Ki Eun Pyo. Kyuho Han is the CEO of MEDiC.

Here are the details of MEDiC's key team members:

Kyuho Han: Co-Founder & CEO of MEDiC.
Contact Info: 1 email address
Hong-pyo Lee: Co-Founder & CTO of MEDiC.
Ki Eun Pyo: Co-Founder of MEDiC.

View details of MEDiC's Founder profiles and Board Members

MEDiC's employee count trend

MEDiC has 17 employees as of May 26. Here is MEDiC's employee count trend over the years:

Uncover MEDiC's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MEDiC include Senti Bio, CRISPR Therapeutics and 64x Bio. Here is the list of Top 10 competitors of MEDiC, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Wellington, Celgene & 10 others	63/100
3rd	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	First Round Capital, Fifty Years & 13 others	61/100
4th	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
5th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Fidelity Investments, Novartis & 12 others	60/100
6th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, Invus & 17 others	58/100
7th	Logomix 2019, San Carlos (United States), Series A	Provider of genome engineering platform to create artificial cells	$22.6M	UTokyo Innovation Platform, Globis Capital Partners ... & 15 others	57/100
8th	OXGENE 2011, Oxford (United Kingdom), Acquired	Provider of a platform for mammalian cell engineering	$28.1M	Mercia, Invesco & 6 others	57/100
9th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	57/100
10th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
15th	MEDiC 2019, San Carlos (United States), Seed	Developer of CRISPR based cancer organoids for clinical trial tests	$13M	Illumina, Wing Venture Capital & 6 others	44/100